Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PRPO vs ACHV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACHV Captures Overall Composite Edge (56.6 HOLD vs 32.2 SELL), While PRPO Leads 4–2 on Growth & Valuation Pillars

ACHV Overall Winner 6-Pillar Tally: PRPO 4 – 2 ACHV Matrix Metrics: PRPO 4 – 6 ACHV

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Precipio, Inc. (PRPO) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.2/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while PRPO wins 4–2 across the 6-pillar growth and valuation breakdown. PRPO trades at $19.96 (15.4x Forward P/E, -5.3% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. PRPO 32.2/100 SELL) and 1.73β · 62% Vol risk profile, whereas PRPO leads top-line expansion (+8.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRPO vs ACHV
PRPO NASDAQ
Precipio, Inc. Common Stock
Laboratory Analytical Instruments
$19.96
-9.81% 1D
Market Cap $39.7M
TTM Revenue $28M
Forward P/E 15.4x
Beta / 30D Vol 1.21β · 96% Vol
Unified Composite Score
32.2 / 100 SELL
Tech 5.0 Fund 31.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.1 · SMA20: $20.38 · SMA50: $22.83
ACHV NASDAQ Head-to-Head Winner
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28

6-Pillar Scorecard Institutional Category Breakdown (PRPO 4 – 2 ACHV)

Columns: Metric · PRPO · ACHV
1. Valuation Multiples PRPO
Forward P/E 15.4x 35.3x
Trailing P/E 15.4x 35.3x
PEG Ratio N/M 17.68x
EV / Revenue 1.4x N/M
2. Growth & Scale PRPO
Revenue Growth (YoY) +8.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28M N/A
Market Cap $39.7M $692.8M
3. Profitability & Quality ACHV
Gross Margin 44.6% N/A
Operating Margin -5.3% 0.0%
Net Profit Margin -4.1% 0.0%
Return on Equity (ROE) -8.0% -845.0%
4. Balance Sheet & Cash Flow PRPO
Cash Generation (TTM) -$56,000 EBITDA -$44M
Cash Flow Margin -0.2% EBITDA Mgn N/A
Net Cash / Leverage $8.29 Book/Sh · -8.0% ROE $46M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHV
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 88.3% (23rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PRPO
OpEx & R&D Intensity 49.9% of Rev ($14M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRPO (4) vs ACHV (6)
Institutional Metric PRPO ACHV Criterion Row Edge
Market Capitalization
Scale
$39.7M $692.8M Larger Scale ACHV
Trailing P/E Ratio
Valuation
15.4x 35.3x Lower Multiple PRPO
Forward P/E Ratio
Valuation
15.4x 35.3x Lower Multiple PRPO
Revenue Growth (YoY)
Growth
+8.3% +0.0% Higher Growth PRPO
Operating Margin (TTM)
Profitability
-5.3% 0.0% Higher Margin ACHV
Net Profit Margin
Profitability
-4.1% 0.0% Higher Margin ACHV
Return on Equity (ROE)
Capital Efficiency
-8.0% -845.0% Higher ROE PRPO
52-Week Range Position
Momentum
14% ($18–$34) 69% ($3–$9) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.21β · 96% Vol 1.73β · 62% Vol Lower Realized Risk ACHV
Unified Institutional Score
Composite Signal
32.2 / 100 (SELL) 56.6 / 100 (HOLD) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
$28M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev 17.68x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$56,000 EBITDA ($8.29 Book/Sh · -8.0% ROE) -$44M ($46M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRPO +4.52 pp
PRPO: -3.98% · ACHV: -8.5%
3M Horizon ACHV +0.82 pp
PRPO: -0.67% · ACHV: +0.15%
6M Horizon ACHV +43.3 pp
PRPO: -22.01% · ACHV: +21.29%
1Y Horizon ACHV +32.64 pp
PRPO: +11.0% · ACHV: +43.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRPO vs ACHV. Trailing 12-month operating profitability (PRPO -5.3% vs ACHV 0.0%) and valuation multiples (PRPO 15.4x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

PRPO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin44.6%
Op. Margin-5.3%
ROE / Fwd P/E-8.0% · 15.4x
ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRPO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRPO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRPO Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $39.7M market capitalization and -5.3% operating margin.
OpEx & R&D Reinvestment 49.9% of Rev ($14M)
90D Engineering Disclosures 0 Published
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRPO vs ACHV Key Questions & Quantitative Answers

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Precipio, Inc. (PRPO) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.2/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while PRPO wins 4–2 across the 6-pillar growth and valuation breakdown. PRPO trades at $19.96 (15.4x Forward P/E, -5.3% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. PRPO 32.2/100 SELL) and 1.73β · 62% Vol risk profile, whereas PRPO leads top-line expansion (+8.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

PRPO leads the Growth & Scale pillar: PRPO posts +8.3% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (44.6% gross margin, -5.3% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PRPO generates $28M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, PRPO deploys 49.9% of Rev ($14M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.

PRPO screens cheaper on headline valuation multiples. PRPO trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-0.2% EBITDA margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRPO (-8.0% ROE) versus ACHV (-845.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PRPO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.21β · 96% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.